Paxlovid availability and prescription requirements
Pro Research Analysisby 
Searched over 200M research papers
Paxlovid Availability: Global and Regional Access
Paxlovid (nirmatrelvir/ritonavir) is an oral antiviral treatment for COVID-19, but its availability varies widely across regions. In low- and middle-income countries (LMICs), access is shaped by a voluntary licensing agreement between Pfizer and the Medicines Patent Pool, which allows 95 LMICs to obtain affordable generic versions. However, many middle-income countries are excluded from this deal and must pay higher prices, limiting widespread access. Additionally, delays in generic production due to bioequivalence testing and limited COVID-19 testing capacity in these regions further restrict timely access to Paxlovid .
In Spain, the national drug agency has set prioritization criteria for Paxlovid access, focusing on high-risk groups such as immunocompromised individuals. Hospital pharmacists play a key role in reviewing prescriptions and ensuring safe use, especially given the high risk of drug-drug interactions 78. In Canada, the province of Québec stands out for granting pharmacists the authority to prescribe Paxlovid directly, which has significantly increased the number of prescriptions filled and improved timely access for patients .
Prescription Requirements: Who Can Prescribe Paxlovid?
Prescription requirements for Paxlovid differ by country and even by region. In the United States, federal emergency authority temporarily allowed pharmacists to prescribe Paxlovid, but with significant restrictions that sometimes conflicted with clinical guidelines. These restrictions have limited the practical utility of pharmacist prescribing and highlighted the challenges of federal versus state oversight. Long-term, broader pharmacist prescriptive authority may depend on state-level legislative changes 14.
In Québec, pharmacists have been authorized to prescribe Paxlovid since April 2022, making it easier for patients to start treatment quickly after a positive COVID-19 test. This policy has been credited with improving public health outcomes and demonstrating the value of pharmacists in pandemic response . In other parts of Canada and the U.S., such direct pharmacist prescribing is less common, and patients typically require a prescription from a physician or nurse practitioner 15.
Safety Considerations and Pharmacy Validation
A major requirement for prescribing Paxlovid is careful assessment of potential drug-drug interactions, as ritonavir can interact with many commonly used medications. Studies from Spain and France emphasize that pharmacists and clinicians must thoroughly review patients’ medication lists and medical histories before dispensing Paxlovid. In Spain, 60% of patients prescribed Paxlovid had potential drug interactions, with serious interactions in 42.9% of cases. In some instances, prescriptions were modified or not dispensed due to these risks 678.
Guidelines recommend that in complex cases, clinicians consult with pharmacology experts to manage interactions and ensure patient safety. In practice, this often means hospital pharmacists validate prescriptions and may recommend holding or adjusting other medications during Paxlovid treatment 2678.
Innovative Models for Equitable Access
Integrated care models, such as virtual pharmacy services, have been developed to streamline Paxlovid access and ensure safety. In Toronto, Canada, an interdisciplinary virtual care team—including physicians, nurse practitioners, and pharmacists—used a streamlined referral process and medication review to provide timely Paxlovid treatment. This model enabled most patients to receive treatment within 24 hours of referral, while also addressing drug interaction risks and supporting marginalized populations .
Conclusion
Paxlovid availability and prescription requirements are shaped by regional policies, regulatory frameworks, and the need for careful management of drug interactions. While some regions have expanded pharmacist prescribing authority to improve access, significant barriers remain in many parts of the world, especially in LMICs and areas with restrictive regulations. Pharmacy validation and integrated care models are essential to ensure safe and equitable access to Paxlovid, particularly for high-risk and complex patient populations 12345678.
Sources and full results
Most relevant research papers on this topic